|
|
| | rafivirumab Basic information |
| Product Name: | rafivirumab | | Synonyms: | rafivirumab;Research Grade Rafivirumab(DVV03902);Research Grade Rafivirumab;Rafivirumab (anti-Rabies virus GP) | | CAS: | 944548-37-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![rafivirumab Structure]() |
| | rafivirumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | rafivirumab Usage And Synthesis |
| Uses | Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails[1][2][3]. | | in vivo | Rafivirumab (3-12 μg/kg,i.m.) together with CR4098 increases survival in syrian hamsters infected with bat rabies viruses[2].
| Animal Model: | Syrian hamsters infected with bat rabies viruses[2].
| | Dosage: | 6, 12, 16, 18 or 24 μg/kg of CL184 (mixture of Rafivirumab and CR4098 in 1:1 protein ratio) | | Administration: | i.m. | | Result: | Increased survival rate. |
| | References | [1] Kramer RA, et al. The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol. 2005 Jul;35(7):2131-45. DOI:10.1002/eji.200526134
[2] Franka R, et al. In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. Trop Med Infect Dis. 2017 Sep 20;2(3):48. DOI:10.3390/tropicalmed2030048
[3] Ejemel M, et al. A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. Sci Rep. 2022 Jun 7;12(1):9403. DOI:10.1038/s41598-022-13527-0 |
| | rafivirumab Preparation Products And Raw materials |
|